Analysis of N-acetyltransferase (NAT2) in three ethnic groups in Tunisia

Therapie

Volumn 55, Issue 3, 2000, Pages 361-369

  Attitallah, S ^a   Bechtel, Y C ^a   Belkahia, Ch ^b   Bechtel, P R ^a  

^a Lab Physiologie et Pharmacologie   (France)

^b CHARLES NICOLLE HOSPITAL   (Tunisia)

Author keywords

Caffeine genetic polymorphism; Genotype; NAT 2; Phenotype; Tunisian ethnicity

Indexed keywords

ACYLTRANSFERASE; CAFFEINE;

ACETYLATION; ADOLESCENT; ADULT; ARAB; ARTICLE; ENZYME ACTIVITY; ETHNIC GROUP; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; PRIORITY JOURNAL; TUNISIA;

ACETYLATION; ACETYLTRANSFERASES; ADOLESCENT; ADULT; ARABS; ETHNIC GROUPS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TUNISIA;

EID: 0033925664     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Evans DAP, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. BMJ 1960; 2: 485-491.
2. Grant DM, Blum M, Meyer UA. Polymorphism of N-acetyltransferase genes. Xenobiotica 1992; 22: 1073-1081.
3. Evans DAP. N-acetyltransferase. Pharmacol Ther 1989; 42: 157-234.
4. Meyer UA. Molecular genetics and the future of pharmacogenetics. Pharmacol Ther 1990; 46: 349-355.
5. Weber WW. The Acetylator Genes and Drug Response. New York: Oxford University Press.
6. Lin HJ, Han ChY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutation in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994; 4: 125-134.
7. Bechtel YC, Bonaiti-Pellié C, Poisson N et al. A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther 1993; 54: 131-141.
8. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 37: 25-79.
9. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983; 33: 591-602.
10. Bechtel PR, Bechtel YC. Interethnic differences in arylamine N-acetyltransferase activity. Clinical consequences. In: Pacifici GM, Fracchia GN, eds. Advances in Drug Metabolism in Man. Brussels/Luxembourg: ECSC-EC-EAEC, 1995: 137-147.
11. Meyer UA. The molecular basis of genetic polymorphisms of drug metabolism. J Pharm Pharmacol 1994; 46: 409-415.
12. Jenne JW. Partial purification and properties of the isoniazid transacetylase in human liver. Its relationship to the acetylation of p-aminosalicylic acid. J Clin Invest 1965; 44: 1992-2002.
13. Blum M, Grant DM, Demierre A, Meyer UA. Nucleotide sequence of a full-length c-DNA for arylamine N-acetyltransferase from rabbit liver. Nucl Acids Res 1989; 17: 3589.
14. Blum M, Grant DM, Demierre A, Meyer UA. Acetylation pharmacogenetics: a gene deletion causes absence of arylamine N-acetyltransferase in liver of slow acetylator rabbits. Proc Natl Acad Sci USA 1989; 86: 9554-9557.
15. Blum M, Grant DM, McBride W et al. Human arylamine N-acetyltransferase genes: isolation, chromosomal localisation, and functional expression. DNA Cell Biol 1990; 3: 193-203.
16. Blum M, Demierre A, Grant DM et al. Molecular mechanism of slow acetylation of drugs and carcinogens in human. Proc Natl Acad Sci USA 1991; 88: 5237-5241.
17. Bendriss EK, Bechtel YC, Paintaud G et al. Acetylation polymorphism expression in patients before and after liver transplantation: influence of host/graft genotypes. Pharmacogenetics 1998; 8: 201-209.
18. Korrapati MR, Sorkin JD, Andres JD et al. Acetylator phenotype in relation to age and gender in the Baltimore longitudinal study of ageing. J Clin Pharmacol 1997; 37: 83-91.
19. Paulsen O, Nilsson LG. Distribution of acetylator phenotype in relation to age and sex in Swedish patients. Eur J Clin Pharmacol 1985; 28: 311-315.
20. Relling MV, Iin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase and CYP1A2 activities. Clin Pharmacol Ther 1992; 52: 643-658.
21. Neitzel HA. A routine method for the establishment of permanent growing lymphoblastoid. Cell Hum Genet 1986; 73: 320-322.